CLINICAL USEFULNESS OF LENVATINIB AS SECOND- LINE TREATMENT FOR HEPATOCELLULAR CARCINOMA FOLLOWING ATEZOLIZUMAB PLUS BEVACIZUMAB FAILURE

被引：0
|
作者：
Hiraoka, Atsushi [1 ]
Tada, Toshifumi [2 ,3 ]
Hirooka, Masashi [2 ,3 ]
Kariyama, Kazuya [2 ,3 ]
Itobayashi, Ei [2 ,3 ]
Kunihiko, Tsuji [2 ,3 ]
Ishikawa, Toru [2 ,3 ]
Toyoda, Hidenori [2 ,3 ]
Hatanaka, Takeshi [2 ,3 ]
Kakizaki, Satoru [2 ,3 ]
Naganuma, Atsushi [2 ,3 ]
Matono, Tomomitsu [2 ,3 ]
Ohama, Hideko [1 ]
Tada, Fujimasa [1 ]
Nouso, Kazuhiro [2 ,3 ]
Hiasa, Yoichi [2 ,3 ]
Kumada, Takashi [2 ,3 ]
机构：
[1] Ehime Prefectural Cent Hosp, Ehime, Japan
[2] Relpec Study Grp, Osaka, Japan
[3] HCC 48 Grp, Osaka, Japan
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4023-A
引用
收藏
页码：S1816 / S1817
页数：2
相关论文
共 50 条
  • [1] Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma
    Komatsu, Shohei
    Yano, Yoshihiko
    Kido, Masahiro
    Kuramitsu, Kaori
    Gon, Hidetoshi
    Fukushima, Kenji
    Urade, Takeshi
    So, Shinichi
    Yamamoto, Atsushi
    Goto, Tadahiro
    Yanagimoto, Hiroaki
    Toyama, Hirochika
    Ueda, Yoshihide
    Kodama, Yuzo
    Fukumoto, Takumi
    ANTICANCER RESEARCH, 2022, 42 (11) : 5479 - 5486
  • [2] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
    Yamaba, Shinpei
    Imai, Yukinori
    Sugawara, Kayoko
    Uchida, Yoshihito
    Fuchigami, Akira
    Uchiya, Hiroshi
    Nakayama, Nobuaki
    Mochida, Satoshi
    PLOS ONE, 2024, 19 (04):
  • [3] Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma -clinical results show importance of hepatic reserve function
    Hiraoka, Atsushi
    Kumada, Takashi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Matono, Tomomitsu
    Kuroda, Hidekatsu
    Yata, Yutaka
    Ohama, Hideko
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Yokohama, Keisuke
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Iijima, Hiroko
    Kaibori, Masaki
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (10) : 624 - 633
  • [4] Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
    Yano, Shigeki
    Kawaoka, Tomokazu
    Johira, Yusuke
    Miura, Ryoichi
    Kosaka, Masanari
    Shirane, Yuki
    Murakami, Serami
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kosaka, Yumi
    Yamaoka, Kenji
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ohno, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Mori, Keiichi
    Arihiro, Kouji
    Kuroda, Shintaro
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Aikata, Hiroshi
    MEDICINE, 2021, 100 (42) : E27576
  • [5] Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Johira, Yusuke
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Miura, Ryoichi
    Murakami, Serami
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kosaka, Yumi
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Sentani, Kazuhiro
    Oue, Naohide
    Arihiro, Koji
    Kuroda, Shintaro
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Chayama, Kazuaki
    Aikata, Hiroshi
    LIVER CANCER, 2022, 11 (02) : 174 - 177
  • [6] Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
    Kosaka, Yumi
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Miura, Ryoichi
    Murakami, Serami
    Johira, Yusuke
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ohno, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Aikata, Hiroshi
    INTERNAL MEDICINE, 2023, 62 (12) : 1771 - 1774
  • [7] Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.
    Yang, JIwon
    Choi, Won-Mook
    Kim, Hyung-Don
    Choi, Jonggi
    Yoo, Changhoon
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 558 - 558
  • [8] Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma
    Yang, Jiwon
    Choi, Won-Mook
    Kim, Hyung-Don
    Choi, Jonggi
    Yoo, Changhoon
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    LIVER CANCER, 2024,
  • [9] Treatment effect of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma aiming at curative conversion therapy
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Taniguchi, Tatsuya
    Kawano, Yutaka
    Masaki, Tsutomu
    Takayama, Tetsuji
    ANNALS OF ONCOLOGY, 2023, 34 : S1399 - S1399
  • [10] Meta analysis of lenvatinib vs. sorafenib following atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
    Budiman, R. A.
    Subroto, Devina R. T.
    Subroto, Dion R. T.
    Hasan, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1384 - S1384
12345